CTOs on the Move

Future Family

www.futurefamily.com

 
Future Family is where women, men and couples start their fertility journey. The company`s mission is to make fertility care accessible and affordable to all.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Future Family raised $10M on 10/18/2018
Future Family raised $100M on 12/12/2018

Similar Companies

febit

febit is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Invetx

Invetx is building the world’s premier biotechnology platform for protein-based therapeutics in animal health. We partner with best-in-class biotechnology companies to apply their deep expertise and extensive capabilities for the discovery and development of novel and advanced veterinary biotherapeutics.

OmniActive Health Technologies

OmniActive was born from Kancor Ingredients, an ingredient supplier rooted in the food and flavoring industry. Kancor has decades of experience extracting pure, quality ingredients from whole foods. With a history in extraction of natural products dating back to 1969, we at OmniActive are well versed in the technologies and processes necessary to provide specialized ingredients to the supplements space, as well as food and beverage companies. Kancor and OmniActive were both founded by the Mariwala family, with a long heritage in the spice industry. Patriarch Kanji Moorarji began trading in spices in 1857, an interest that continues to the present day. This history is reflected in the strength of our supply chain and raw material sourcing.

CHUL Research Center

CHUL Research Center is a Quebec, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scipher Medicine

Most patients who are prescribed blockbuster therapies today don`t respond to the treatment, costing the health care industry billions in wasted drugs while patients continue to suffer. Scipher`s platform identifies which drug will work based on the patient`s fundamental disease biology, and not based on symptoms, disease classification, or medical bias. A simple test predicts which drug he/she will respond to, ensuring that most optimal treatment is prescribed from day one. The molecular data generated by our tests is then used to fuel novel target discovery to address a clear unmet medical need in patients who do not respond to any existing therapy.